What is it about?
The importance of the use of biomarkers for a better selection of patients who should be candidates for autologous hematopoietic stem cell transplant in multiple sclerosis.
Featured Image
Why is it important?
Because this modality of treatment in severe cases of MS works better as long as the patient meets some criteris (younger than 45, aggressive course of disease, refractory response to therapy).
Perspectives
To motivate current researchers on aHSCT and multiple sclerosis to create an international panel for adoption of a protocol to apply use of biomarkers (blood and/or spinal fluid) for better selection of patients with MS.
Dr. Carlos A Mora
MedStar Georgetown University Hospital
Read the Original
This page is a summary of: Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up, Journal of Clinical & Cellular Immunology, January 2016, OMICS Publishing Group,
DOI: 10.4172/2155-9899.1000455.
You can read the full text:
Contributors
The following have contributed to this page
